The performance characteristics and diagnostic value of a monoclonal antibody-based radioimmunoassay for serum total thyroxine (Mallinckrodt) are described. Between-batch precision (coefficient of Variation) was 10.4% at 87 nmol/1 and 3.3% at 185 nmolA Scatchard analysis revealed a linear plot with a K a of 5.4 x 10 8 1/mol. \ Sensitivity was 4.5 nmol/1 of thyroxine. An association study showed that the assay reached equilibrium well within the specified incubation time. Cross-reaction of triiodothyronine and reverse triiodothyronine in the assay was 0.6% and 25.0% respectively. Analytical recovery was 91-110%. Linearity was well demonstrated but dilutions of a high concentration of thyroxine in serum did not parallel the Standard curve. The correlation coefficient for comparison with a polyclonal antibody assay was 0.95 for 83 patients. The diagnostic accuracy of the monoclonal antibody assay was adequate for most patients with thyroid disease, pregnant women, oral contraceptive users and subjects on thyroxine-replacement therapy. Measurement of total thyroxine by a monoclonal antibody-based method shows no definite advantage over the conventional polyclonal antibody assay. 
Introduction
Monoclonal antibodies, produced by classical hybridoma techniques (l, 2) offer several advantages for the purposes of radioimmunoassay (RIA), namely monospecificity and elimination of the bleed-tobleed Variation which is associated with animal antisera (3, 4) . Commercial assay kits, using monoclonal antibody technology, have achieved relatively wide use in the estimation of hormones such äs thyrotropin and chorionic gonadotropin because assays employing classical polyclonal antisera to these hormones display predictable cross-reaction with structurally-related molecules (5) . However the role of monoclonal antibody technology in the assay of a hormone such äs total thyroxine (T4) is uncertain äs there are already a large number of excellent commercial kits, utilizing polyclonal antisera, available for this purpose (6, 7) .
The aim of this present study was to examine the value of using ä monoclonal antibody System for the estimation of T4 by comparing the laboratory and clinical performance of the new monoclonal antibody sectionally processed coated tube (SPAC) total T 4 kit from Mallinckrodt with that of a well established conventional T 4 assay (Amerlex: Amersham International) (8, 9) .
Materials and Methods
All sera were assayed for total T 4 , triiodpthyronine (T 3 ) uptake ratio, free T 4 (FT 4 ) and T 3 , and the free thyroxine index (FTI); computed by multiplying the T 4 concentration by the T 3 uptake ratio. Reference intervals, for all of these parameters, were determined in our laboratory. Within-batch precision of the T 4 kits was evaluated by assaying three different concentrations of a lyophilized control material 20 times in a single batch (Ortho tri-level ligand assay control, lot no. LIGX01; Ortho Diagnostics Systems, Inc., Raritan, NJ 08869). Between-batch precision was assessed by testing three concentrations of ligand once per day for seven days.
Sensitivity is defined in this study äs the 'minimal detection limit' of an assay (10) . It was characterised, for each T 4 assay, by using 20 replicates of a zero calibrator to calculate the concentration which corresponds to the value for counts per minute that is two Standard deviations from the mean.
An association study was performed, with low, normal and high T 4 concentration sera, to determine the time needed for the reactants to reach equilibrium. The specificity of the antibody in each T 4 kit was studied by comparing the molar ratio (expressed äs a percentage) between the quantity of T 4 and the quantity of the structurally related thyroid hormones (T 3 and reverse T 3 (rT 3 )) which cause 50% displacement of the T 4 tracer. T 4 and T 3 were obtained from the Sigma Chemical Company and rT 3 from Henning Berlin.
Recovery was studied by assaying aliquots of the same hypothyroid sample to which were added known and increasing amounts of T 4 Standard. Recoveries were then calculated, äs percentages, from the quotient of observed and calculated T 4 concentration. Parallelism and linearity were determined by assaying dilutions of a high concentration of T 4 in serum with a buffer solution containing, per litre, l g of bovine serum albumin, 150 mmol of NaCl, and 67 mmol of phosphate buffer, pH 7.3^.
Patients
Thyroid Status was determined using assays of serum FT 4 , followed by assays of serum T 3 or thyrotropin (TSH) where appropriate. Subjects were then classified according to biochemical and clinical findings äs follows:
Euthyroid controls: Fifty three healthy hospital and laboratory staff (20 men, 33 women).
Patients wiih thyroid disease: Fifteen hyperthyroid patients (4 men, 1 1 women) were all clinically hyperthyroid and had FT 4 corn centrations > 20 pmol/ and T 3 concentrations > 2.5 nmol/l. Fifteen hypothyroid patients (2 men, 13 women) were all clinically hypothyroid and had FT 4 concentrations <10 pmpl/l and thyrotropin levels >6 iiiU/1, T 3 values were within normal limits in nifte hypothyroid patients. Patients on thyroxine^replacement therapy: 20 patients (2 men, 18 women). All patients were clinically controlled on thyroxine and had. normal FT 4 concentrations.
Euthyroid subjects with increases in thyroxine^binding globulin

Statistical analysis
The F-test was used for comparison of precision between the two methods anälysed, Student's paired t-test for comparison of values between both T 4 kits, and Pearson's correlation coefficient (r) to show the degree of linear association among the different variables. Further statistical analyses included Studenfs t-statistics for tests on regression coefficients (11) and the unpaired t-test for comparing means of different determinations with normal control mean values, for the various groups under study. A p value of 0.05 was considered significant.
Results and Discussion
Laboratory evaluation
Precision
The within^batch and between-batch precision for Amerlex and MCA (SPAC) T4 kits is shown in table 1. The performance of the Amerlex kit at three different concentrations was judged to be acceptable according to the criteria of Tanks (12), i.e. twice the coefficient of Variation (CV) should be <20%, whereas the between-batch preeision for the MCA (SPAC) T 4 kit was >10% at low and normal concentrations of T 4 . These variations were higher than those reported in several studies (8, 13 ) but similar to others (6, 7). However over the ränge of concentrations studies, there was no statistical difference in precision between the two methoc^ (F-test). The ob-served difference in precision between methods most likely arises from the inherent problems of coatedtube technology (10, 14) rather than from the nature of the reagents such äs antibody type.
Tab. l. Within-batch and between-batch precision of 7*4 kits äs determined with low-, medium-, and high-concentration control sera. (4) . The K a values for both antibodies were similar to those reported in other RIA T 4 kits (6, 7). Although the calculated K a value for the Amerlex antibody was slightjy higher than that of the monoclonal antibody, both were of sufficiently high affinity to provide assays with sensitivities greater than necessary for determination of serum T 4 (minimal detectable dose for Amerlex T 4 and MCA (SPAC) T 4 were 1.5 nmol/1 and 4.5 nmol/1 respectively).
Association studies showed that the MCA (SPAC) T 4 method reached virtüal equilibrium in the specified incubation tiine (one hour) at the three .different T 4 concentrations studiedi, whereas Amerlex achieved equilibrium befpre 45 minutes (stated incubation time), only at a high T 4 concentration. Amerlex reactions proceeded for two hours without reaching equilibrium at normal and low T 4 concentrations.
Intermethod comparison
Using 83 serum sanjples, there was a high correlation (r = 0.95 p < 0.001) between T 4 levels measured in the monoclonal antibody assay and those measured in the conventional antiserum RIA. This suggests that the monoclonal antibody is directed towards the same antigenic sites on T 4 äs the polyclonal antiserum. The relationship found was MCA (SPAC) T 4 = 0.875x (Amerlex T 4 ) + 17.218. The slope of the regression line was significantly different from unity (p < 0.001) and the intercept statistically different from zero (p < 0.001), indicating that the MCA (SPAC) T 4 assay produces higher values than those of Amerlex T 4 throughout most of the assay ränge. In contrast, T 4 levels in low-, medium-and high-concentration control sera were lower when measured by the MCA (SPAC) T 4 assay than by Amerlex T 4 (tab. 1).
There was very little cross-reaction of TS and rTa in the Amerlex T 4 assay (2.7% and 1.1% respectively) and T 3 with T 4 in the MCA (SPAC) assay (0.6%). However cross-reaction of rTa in the monoclonal T 4 assay was high (25.0%). Since, in normal subjects, rT3 circulated at a concentration <1% than that of T 4 (16) , this cross-reaction would be unimportant in practice.
Recoveries
The Amerlex T 4 method gave a mean recovery of 98% (ränge 95-102%) while the MCA (SPAC) method averaged a recovery of 100% (ränge 91-110%). As no single recovery was less than 85% or greater than 115%, the recoveries found for both methods were acceptable according to the criterion of Logan (17) .
The regression lines calculated for the correlation of added amount vs expected amount indicated that there were excellent linear recoveries in the monoclonal antibody and conventional antiserum RIA's (r = 1.00 for both assays). In addition their slopes were not significantly different from unity nor intercepts statistically different from zero (slopes and intercepts for Amerlex and MCA (SPAC) T 4 , respectively, were 1.06-2.43 and 1.05, -2.25). These results indicate that there is quantitative recovery in both assays independent of the concentration of T 4 to be measured.
Test of parallelism
Amerlex and MCA (SPAC) T 4 methods produced good linearity on dilution throughout the assay ränge (r = 1.00 for both assays). The slope of the line for experimental values vs expected values was not significantly different from unity for the Amerlex assay (slope = 1.00). In contrast the MCA (SPAC) T 4 assay failed to show parallelism (slope = 0.81, p < 0.01). The non-parallelism, indicating interference in the monoclonal antibody assay by factors other than those which can be clearly identified by their physiochemical similarity to T 4 (10), could explain the higher MCA (SPAC) T 4 values in patient's serum compared with those determined by the Amerlex method. Table 2 shows means for FT 4 and results for the MCA (SPAC) and Amerlex T 4 kits in six clinical groups. The percentage of patients in these groups whose values lie outside reference intervals for FT 4 and the two T 4 kits is also shown.
Clinical evaluation
Patients with thyroid disease
The mean values for T 4 by both methods -äs expected -were increased (p < 0.001) in hyperthyroidism. In this gfoup one patient (7%) had a normal T 4 when measured by Amerlex whereas T 4 values assayed by the MCA (SPAC) kit were within the euthyroid ränge in four patients (27%). Amerlex and MCA (SPAC) T 4 values were significantly decreased (p < 0.001) in hypothyroid patients. These patients were distinguished with 93% accuracy frorn normal subjects by the Amerlex T 4 kit (tab. 2) whereas only 73% of hypothyroid patients had MCA (SPAC) T 4 values below normal Kmits.
Thus T 4 values measured by the conventional antibody RIA were a slightly more sensitive indicator of thyroid disease than those assayed by the monoclo·n al antibody assay. 
Subjects with increased thyroid Hormone binding capacity
The concentration of TBG progressively increases with the duration of pregnancy (18, 19) . Therefore -äs expected -T 4 values by both methods were significantly increased (p < 0.001) äs compared with the control group in third trimester pregnants. In these women, more than one-half (55%) of their T 4 values by Amerlex were in the hyperthyrqid fange whilst about a third (35%) of T 4 values assayed by MCA (SPAC) were elevated.
In oral contraceptive users, T 4 values by both methods were increased (p < 0.001), äs a direct consequence of elevated TBG concentrations. Amerlex and MCA (SPAC) T 4 values were elevated in 30% and 25% of patients on oral contraceptives, respectively.
Therefore, in sera of pregnant women and oral contraceptive users, the T 4 value was a more appropriate reflection of TBG concentration, when measured by the conventional RIA than by the monoclonal antibody assay. All 20 patients controlled on thyroxinereplacement therapy gave normal T 4 values by Amerlex and MCA (SPAC) methods. Hence concentrations measured by the monoclonal antibody assay and by the conventional antibody RIA appeared to be of equivalent välüe in moiiitoring thyroxine-treated patients.
Correlation beiween FTI and FT 4
There were good correlations between FT 4 concentraäion and FT1 values derived from each of the T 4 methods in euthyroid control suBjects and patients with thyroid disease (Ainerlex, r = 0.81; p < 0.001 and MCA (SPAC), r = 0.78; p < 0.001). Thus FTI values derived from either the conventional or the monoclonal antibody T 4 assay, were equally good in reflecting a patient's true thyroid Status.
Conclusions
In conclusion, the monoclonal antibody used in the Mallinckrodt (SPAC) T 4 had a similar affinity constant to that of a polyclonal antiserum and showed a clinically insignificant but high cross-reaction with the structurally-related thyroid hormone, rTa. In addition, the assay showed good sensitivity, quantitative recoveries and technical simplicity. Furthermore it demonstrated acceptable diagnostic accuracy, despite the slightly lower sensitivity of the assay äs an index of thyroid Status in thyroid disease, compared with that of a polyclonal antibody RIA. Therefore, in conclusion, a monoclonal antibody T 4 assay is suitable for use in the clinical laboratory, but it offers no significant advantages over a RIA employing a conventional polyclonal antiserum.
